Association of the G-463A myeloperoxidase gene polymorphism with renal disease in African Americans with systemic lupus erythematosus

Journal of Rheumatology

Volumn 34, Issue 10, 2007, Pages 2028-2034

  Bouali, Henda ^a   Nietert, Paul ^a   Nowling, Tamara M ^a   Pandey, Janardan ^a   Dooley, Mary Anne ^b   Cooper, Glinda ^c   Harley, John ^d   Kamen, Diane L ^a   Oates, Jim ^a   Gilkeson, Gary ^a,e  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b University of North Carolina Affiliated Hospitals   (United States)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^d OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^e RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

African American; Lupus nephritis; Myeloperoxidase; Polymorphism; Systemic lupus erythematosus

Indexed keywords

MYELOPEROXIDASE;

ADULT; AFRICAN AMERICAN; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENETIC ASSOCIATION; HUMAN; INFLAMMATION; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; AFRICAN AMERICANS; COHORT STUDIES; FEMALE; GENOTYPE; HUMANS; KIDNEY DISEASES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PEROXIDASE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS (GENETICS); RANDOM ALLOCATION;

EID: 35148852109     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Klebanoff SJ. Myeloperoxidase: friend and foe. J Leukoc Biol 2005;77:598-625.
2. Pero RW, Sheng Y, Olsson A, Bryngelsson C, Lund-Pero M. Hypochlorous acid/N-chloramines are naturally produced DNA repair inhibitors. Carcinogenesis 1996;17:13-8.
3. Malle E, Buch T, Grone HJ. Myeloperoxidase in kidney disease. Kidney Int 2003;64:1956-67.
4. O'Brien PJ. Peroxidases. Chem Biol Interact 2000;129:113-39.
5. Abu-Soud HM, Hazen SL. Nitric oxide modulates the catalytic activity of myeloperoxidase. J Biol Chem 2000;275:5425-30.
6. Abu-Soud HM, Hazen SL. Nitric oxide is a physiological substrate for mammalian peroxidases. J Biol Chem 2000;275:37524-32.
7. Lefkowitz DL, Roberts E, Grattendick K, et al. The endothelium and cytokine secretion: the role of peroxidases as immunoregulators. Cell Immunol 2000;202:23-30.
8. Austin GE, Lam L, Zaki SR, et al. Sequence comparison of putative regulatory DNA of the 5′ flanking region of the myeloperoxidase gene in normal and leukemic bone marrow cells. Leukemia 1993;7:1445-50.
9. Kumar AP, Piedrafita FJ, Reynolds WF. Peroxisome proliferator-activated receptor gamma ligands regulate myeloperoxidase expression in macrophages by an estrogen-dependent mechanism involving the -463GA promoter polymorphism. J Biol Chem 2004;279:8300-15.
10. Hoy A, Tregouet D, Leininger-Muller B, et al. Serum myeloperoxidase concentration in a healthy population: biological variations, familial resemblance and new genetic polymorphisms. Eur J Hum Genet 2001;9:780-6.
11. Rutgers A, Heeringa P, Giesen JE, Theunissen RT, Jacobs H, Tervaert JW. Neutrophil myeloperoxidase activity and the influence of two single-nucleotide promoter polymorphisms. Br J Haematol 2003;123:536-8.
12. Van Schooten FJ, Boots AW, Knaapen AM, et al. Myeloperoxidase (MPO) -463 G-A reduces MPO activity and DNA adduct levels in bronchoalveolar lavages of smokers. Cancer Epidemiol Biomarkers Prev 2004;13:828-33.
13. Uramoto KM, Michet CJ Jr, Thumboo J, Sunku J, O'Fallon WM, Gabriel SE. Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992. Arthritis Rheum 1999;42:46-50.
14. Pisetsky DS, Gilkeson G, St. Clair EW. Systemic lupus erythematosus. Diagnosis and treatment. Med Clin North Am 1997;81:113-28.
15. Evans MD, Cooke MS, Akil M, Samanta A, Lunec J. Aberrant processing of oxidative DNA damage in systemic lupus erythematosus. Biochem Biophys Res Commun 2000;273:894-8.
16. Boumpas DT, Fessier BJ, Austin HA 3rd, Balow JE, Klippel JH, Lockshin MD. Systemic lupus erythematosus: emerging concepts. Part 2: Dermatologic and joint disease, the antiphospholipid antibody syndrome, pregnancy and hormonal therapy, morbidity and mortality, and pathogenesis. Ann Intern Med 1995;123:42-53.
17. Sprovieri SR, Sens YA. Polymorphisms of the renin-angiotensin system genes in Brazilian patients with lupus nephropathy. Lupus 2005;14:356-62.
18. Hillegass LM, Griswold DE, Brickson B, Albrightson-Winslow C. Assessment of myeloperoxidase activity in whole rat kidney. J Pharmacol Methods 1990;24:285-95.
19. Brouwer E, Huitema MG, Mulder AH, et al. Neutrophil activation in vitro and in vivo in Wegener's granulomatosis. Kidney Int 1994;45:1120-31.
20. Heeringa P, Steenbergen E, van Goor H. A protective role for endothelial nitric oxide synthase in glomerulonephritis. Kidney Int 2002;61:822-5.
21. Malle E, Woenckhaus C, Waeg G, Esterbauer H, Grone EF, Grone HJ. Immunological evidence for hypochlorite-modified proteins in human kidney. Am J Pathol 1997;150:603-15.
22. Cooper GS, Parks CG, Treadwell EL, St. Clair EW, Gilkeson GS, Dooley MA. Occupational risk factors for the development of systemic lupus erythematosus. J Rheumatol 2004;31:1928-33.
23. Kamen DL, Barron M, Hollis BW, et al. Correlation of vitamin D deficiency with lupus disease measures among Sea Island Gullah African Americans [abstract]. Arthritis Rheum 2005;52 Suppl:S180.
24. Quintero-Del-Rio AI, Kelly JA, Kilpatrick J, James JA, Harley JB. The genetics of systemic lupus erythematosus stratified by renal disease: linkage at 10q22.3 (SLEN1), 2q34-35 (SLEN2), and 11p15.6 (SLEN3). Genes Immun 2002;3 Suppl 1:S57-62.
25. London SJ, Lehman TA, Taylor JA. Myeloperoxidase genetic polymorphism and lung cancer risk. Cancer Res 1997;57:5001-3.
26. Shen N, Tsao BP. Current advances in the human lupus genetics. Curr Rheumatol Rep 2004;6:391-8.
27. Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003;349:1526-33.
28. Oates JC, Levesque MC, Hobbs MR, et al. Nitric oxide synthase 2 promoter polymorphisms and systemic lupus erythematosus in African-Americans. J Rheumatol 2003;30:60-7.
29. Karassa FB, Trikalinos TA, Ioannidis JP. The Fc gamma RIIIA-F158 allele is a risk factor for the development of lupus nephritis: a meta-analysis. Kidney Int 2003;63:1475-82.
30. Karassa FB, Trikalinos TA, Ioannidis JP. Role of the Fc-gamma receptor IIa polymorphism in susceptibility to systemic lupus erythematosus and lupus nephritis: a meta-analysis. Arthritis Rheum 2002;46:1563-71.
31. Piedrafita FJ, Molander RB, Vansant G, Orlova EA, Pfahl M, Reynolds WF. An Alu element in the myeloperoxidase promoter contains a composite SP1-thyroid hormone-retinoic acid response element. J Biol Chem 1996;271:14412-20.
32. Oates JC, Christensen EF, Reilly CM, Self SE, Gilkeson GS. Prospective measure of serum 3-nitrotyrosine levels in systemic lupus erythematosus: correlation with disease activity. Proc Assoc Am Physicians 1999;111:611-21.
33. Kumar AP, Ryan C, Cordy V, Reynolds WF. Inducible nitric oxide synthase expression is inhibited by myeloperoxidase. Nitric Oxide 2005;13:42-53.
34. Reynolds WF, Chang E, Douer D, Ball ED, Kanda V. An allelic association implicates myeloperoxidase in the etiology of acute promyelocytic leukemia. Blood 1997;90:2730-7.
35. Nagra RM, Becher B, Tourtellotte WW, et al. Immunohistochemical and genetic evidence of myeloperoxidase involvement in multiple sclerosis. J Neuroimmunol 1997;78:97-107.
36. Brennan M, Gaur A, Pahuja A, Lusis AJ, Reynolds WF. Mice lacking myeloperoxidase are more susceptible to experimental autoimmune encephalomyelitis. J Neuroimmunol 2001;112:97-105.
37. Cascorbi I, Henning S, Brockmoller J, et al. Substantially reduced risk of cancer of the aerodigestive tract in subjects with variant -463A of the myeloperoxidase gene. Cancer Res 2000;60:644-9.
38. Reynolds WF, Rhees J, Maciejewski D, et al. Myeloperoxidase polymorphism is associated with gender specific risk for Alzheimer's disease. Exp Neurol 1999;155:31-41.
39. Reynolds WF, Hiltunen M, Pirskanen M, et al. MPO and APOE-epsilon4 polymorphisms interact to increase risk for AD in Finnish males. Neurology 2000;55:1284-90.
40. Pope SK, Kritchevsky SB, Ambrosone C, et al. Myeloperoxidase polymorphism and cognitive decline in older adults in the Health, Aging, and Body Composition Study. Am J Epidemiol 2006;163:1084-90.
41. Nikpoor B, Turecki G, Fournier C, Theroux P, Rouleau GA. A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians. Am Heart J 2001;142:336-9.
42. Pecoits-Filho R, Stenvinkel P, Marchlewska A, et al. A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients. Kidney Int Suppl 2003;84:S172-6.
43. Reynolds WF, Stegeman CA, Tervaert JW. -463 G/A myeloperoxidase promoter polymorphism is associated with clinical manifestations and the course of disease in MPO-ANCA-associated vasculitis. Clin Immunol 2002;103:154-60.
44. Castellani LW, Chang JJ, Wang X, Lusis AJ, Reynolds WF. Transgenic mice express human MPO -463G/A alleles at atherosclerotic lesions, developing hyperlipidemia and obesity in -463G males. J Lipid Res 2006;47:1366-77.
45. Makela R, Karhunen PJ, Kunnas TA, et al. Myeloperoxidase gene variation as a determinant of atherosclerosis progression in the abdominal and thoracic aorta: an autopsy study. Lab Invest 2003;83:919-25.
46. Milla C, Yang S, Cornfield DN, et al. Myeloperoxidase deficiency enhances inflammation after allogeneic marrow transplantation. Am J Physiol Lung Cell Mol Physiol 2004;287:L706-14.
47. Eiserich JP, Baldus S, Brennan ML, et al. Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science 2002;296:2391-4.
48. McMillen TS, Heinecke JW, LeBoeuf RC. Expression of human myeloperoxidase by macrophages promotes atherosclerosis in mice. Circulation 2005;111:2798-804.
49. Brennan ML, Anderson MM, Shih DM, et al. Increased atherosclerosis in myeloperoxidase-deficient mice. J Clin Invest 2001;107:419-30.